At a glance
ClinicalIndex Comparison RecordN/ACompleted· 696 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PREVENAR13(REGISTRIED) SUSPENSION LIQUID FOR INJECTION DRUG USE INVESTIGATION - ADULTS AGED 65 YEARS OR OLDER
In Brief
An observational study for Adult Not Younger Than 65 Years. Completed, enrolled 696 participants across 1 site.
Detailed Summary
This study aims to understand the following items in post-marketing actual clinical settings to evaluate the safety of 13vPnC administered as a single dose in the elderly (adults aged 65 years or older). 1. To confirm the use in actual clinical settings 2. To confirm the occurrence of adverse events
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Not Younger Than 65 Years
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJan 2017
Primary CompletionJan 2017
TodayJul 2026
First PostedJan 9, 2017
Enrollment StartJun 15, 2015
Primary CompletionJan 31, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.5 years ago